Skip to main content
SpringerLink
Log in

Patiromer + spironolactone cost effective in HF with hyperkalaemia

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Randomized Aldactone Evaluation Study

  2. A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia

  3. New York Heart Association

  4. 2016 US dollars

Reference

  • Bounthavong M, et al. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. PharmacoEconomics : 8 Sep 2018

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patiromer + spironolactone cost effective in HF with hyperkalaemia. Reactions Weekly 1720, 13 (2018). https://doi.org/10.1007/s40278-018-51807-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-51807-6

Search

Navigation